SlideShare a Scribd company logo
ALS to confront deadly melanoma
January 20, 2003 10:00
By Jeff Meredith
CHICAGO - Advanced Life Sciences continues to build on a strong
patent portfolio through its licensing agreement with the University of
Illinois at Chicago (UIC).
On December 17, 2002, the U.S. Patent and Trademark Office granted
a patent to UIC for a potential anti-cancer agent treating malignant
melanoma, a deadly form of skin cancer. To be developed by Advanced
Life Sciences, betulinic acid is a compound derived from birch bark
that promotes the death of cancer cells.
Woodridge-based Advanced Life Sciences is a three-year old spinout of
MediChem Research, Inc., which has focused on the manufacture of
naturally-derived products. A UIC research team discovered betulinic
acid's therapeutic properties as a part of a collaborative drug discovery
group supported by the National Cancer Institute. The compound was
originally taken from the stem bark of a plant in Zimbabwe, but
researchers discovered that the active agent was more accessible in
birch bark.
"It is a natural product isolated from birch bark and our expertise in
working with the natural products is using medicinal chemistry to be
able to synthesize that molecule and continue to optimize its
properties so it can be a drug in the clinic," said John Flavin, CFO of
Advanced Life Sciences, in a September interview with I-Street.
Dr. John Pezzuto, M.D., Ph.D., formerly with UIC's College of Pharmacy
and now dean of Purdue University's College of Pharmacy, Nursing and
Health Services and Dr. Tapas K. Das Gupta, M.D., Ph.D., professor and
head of Surgical Oncology at UIC's College of Medicine, are the
primary inventors of the technology. UIC filed for a patent in August
2000.

More Related Content

More from Jeff Meredith

Adtr11 pickup report_022211
Adtr11 pickup report_022211Adtr11 pickup report_022211
Adtr11 pickup report_022211
Jeff Meredith
 
Research Findings: August-September 2015
Research Findings: August-September 2015Research Findings: August-September 2015
Research Findings: August-September 2015
Jeff Meredith
 
MX Analyst Deck
MX Analyst DeckMX Analyst Deck
MX Analyst Deck
Jeff Meredith
 
BusinessImpactStudy
BusinessImpactStudyBusinessImpactStudy
BusinessImpactStudy
Jeff Meredith
 
Boeing’s diversification strategy
Boeing’s diversification strategy Boeing’s diversification strategy
Boeing’s diversification strategy
Jeff Meredith
 
RFIDforDefense2006.pdf.
RFIDforDefense2006.pdf.RFIDforDefense2006.pdf.
RFIDforDefense2006.pdf.
Jeff Meredith
 
Spam
SpamSpam
Women in Bioscience
Women in BioscienceWomen in Bioscience
Women in Bioscience
Jeff Meredith
 
Oxomate
OxomateOxomate
Oxomate
Jeff Meredith
 
NASA
NASANASA
Solar
SolarSolar
WebDesignBook
WebDesignBookWebDesignBook
WebDesignBook
Jeff Meredith
 
Neuronautics
NeuronauticsNeuronautics
Neuronautics
Jeff Meredith
 
FAQ-6
FAQ-6FAQ-6
FAQ-how-to-demonstrate-ROI
FAQ-how-to-demonstrate-ROIFAQ-how-to-demonstrate-ROI
FAQ-how-to-demonstrate-ROI
Jeff Meredith
 
DMM Competitor Analysis DigitalV2
DMM Competitor Analysis DigitalV2DMM Competitor Analysis DigitalV2
DMM Competitor Analysis DigitalV2
Jeff Meredith
 
DigitalTravelMAIN10
DigitalTravelMAIN10DigitalTravelMAIN10
DigitalTravelMAIN10
Jeff Meredith
 

More from Jeff Meredith (17)

Adtr11 pickup report_022211
Adtr11 pickup report_022211Adtr11 pickup report_022211
Adtr11 pickup report_022211
 
Research Findings: August-September 2015
Research Findings: August-September 2015Research Findings: August-September 2015
Research Findings: August-September 2015
 
MX Analyst Deck
MX Analyst DeckMX Analyst Deck
MX Analyst Deck
 
BusinessImpactStudy
BusinessImpactStudyBusinessImpactStudy
BusinessImpactStudy
 
Boeing’s diversification strategy
Boeing’s diversification strategy Boeing’s diversification strategy
Boeing’s diversification strategy
 
RFIDforDefense2006.pdf.
RFIDforDefense2006.pdf.RFIDforDefense2006.pdf.
RFIDforDefense2006.pdf.
 
Spam
SpamSpam
Spam
 
Women in Bioscience
Women in BioscienceWomen in Bioscience
Women in Bioscience
 
Oxomate
OxomateOxomate
Oxomate
 
NASA
NASANASA
NASA
 
Solar
SolarSolar
Solar
 
WebDesignBook
WebDesignBookWebDesignBook
WebDesignBook
 
Neuronautics
NeuronauticsNeuronautics
Neuronautics
 
FAQ-6
FAQ-6FAQ-6
FAQ-6
 
FAQ-how-to-demonstrate-ROI
FAQ-how-to-demonstrate-ROIFAQ-how-to-demonstrate-ROI
FAQ-how-to-demonstrate-ROI
 
DMM Competitor Analysis DigitalV2
DMM Competitor Analysis DigitalV2DMM Competitor Analysis DigitalV2
DMM Competitor Analysis DigitalV2
 
DigitalTravelMAIN10
DigitalTravelMAIN10DigitalTravelMAIN10
DigitalTravelMAIN10
 

ALS

  • 1. ALS to confront deadly melanoma January 20, 2003 10:00 By Jeff Meredith CHICAGO - Advanced Life Sciences continues to build on a strong patent portfolio through its licensing agreement with the University of Illinois at Chicago (UIC). On December 17, 2002, the U.S. Patent and Trademark Office granted a patent to UIC for a potential anti-cancer agent treating malignant melanoma, a deadly form of skin cancer. To be developed by Advanced Life Sciences, betulinic acid is a compound derived from birch bark that promotes the death of cancer cells. Woodridge-based Advanced Life Sciences is a three-year old spinout of MediChem Research, Inc., which has focused on the manufacture of naturally-derived products. A UIC research team discovered betulinic acid's therapeutic properties as a part of a collaborative drug discovery group supported by the National Cancer Institute. The compound was originally taken from the stem bark of a plant in Zimbabwe, but researchers discovered that the active agent was more accessible in birch bark. "It is a natural product isolated from birch bark and our expertise in working with the natural products is using medicinal chemistry to be able to synthesize that molecule and continue to optimize its properties so it can be a drug in the clinic," said John Flavin, CFO of Advanced Life Sciences, in a September interview with I-Street. Dr. John Pezzuto, M.D., Ph.D., formerly with UIC's College of Pharmacy and now dean of Purdue University's College of Pharmacy, Nursing and Health Services and Dr. Tapas K. Das Gupta, M.D., Ph.D., professor and head of Surgical Oncology at UIC's College of Medicine, are the primary inventors of the technology. UIC filed for a patent in August 2000.